Bobby joined the IP Group team following the combination with Touchstone Innovations, having joined that business in 2015. Prior to Touchstone Innovations, Bobby was Investment Director of Novo Seeds, the early stage investment arm of Novo AS. He led investments there in several seed stage companies including Acesion, Avilex, RSPR Pharma, and Contera Pharma (exited).
Bobby has 17 years of experience in the life science industry including drug development (Maxygen), business development (LEO pharma) and venture capital investing.
Bobby obtained his PhD in Biology from University of Virginia (but did all the work at Imperial College London), and his BS in Biochemistry at the University of Rochester.